Cargando…

Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report

Mucopolysaccharidosis type I S (MPS IS) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the IDUA gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Enzyme replacement therapy (ERT) reduces lysosomal storage in the liver and improves clinical manifestatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasilevska, Lauma, Auzenbaha, Madara, Grinfelde, Ieva, Skangale, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424730/ https://www.ncbi.nlm.nih.gov/pubmed/36052356 http://dx.doi.org/10.3389/fped.2022.973193

Ejemplares similares

Implication of Genetic Testing and Pregnancy Outcome in a Woman with Unbalanced Translocation t(1;6)
por: Jurčenko, Marija, et al.
Publicado: (2022)

Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I
por: Grant, Nathan, et al.
Publicado: (2021)

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
por: Li, Ying, et al.
Publicado: (2022)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Case Report: Diagnosis of Mucopolysaccharidosis Type IVA With Compound Heterozygous Galactosamine-6 Sulfatase Variants and Biopsy of Replaced Femoral Heads
por: Ma, Yiyang, et al.
Publicado: (2022)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series
por: İnci, Aslı, et al.
Publicado: (2021)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I
por: Le, Steven Q., et al.
Publicado: (2017)

Two Cases of Leigh Syndrome in One Family: Diagnostic Challenges and Clinical Management Experience in Latvia
por: Katkevica, Arta, et al.
Publicado: (2021)

Mucopolysaccharidosis Type I Diagnosed by Aortic and Mitral Valve Replacement
por: Sherwood, Dalton J., et al.
Publicado: (2021)

The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis
por: Qu, Yuhua, et al.
Publicado: (2022)

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
por: Hsu, Yu-Hone, et al.
Publicado: (2017)

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

The First Registered Type 0 Spinal Muscular Atrophy Patient in Latvia: Call for Change in Prenatal Diagnostic Procedures
por: Čupāne, Tīna Luīze, et al.
Publicado: (2023)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy
por: Mack, Heather G., et al.
Publicado: (2017)

Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
por: Sugiura, Kenta, et al.
Publicado: (2020)

Application of whole-genome sequencing in a case study of renal tuberculosis in a child
por: Aleinikova, Darja, et al.
Publicado: (2020)

Relationship between serum phosphate and mortality in critically ill children receiving continuous renal replacement therapy
por: Zhou, Xiong, et al.
Publicado: (2023)

12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment
por: Gabrielli, Orazio, et al.
Publicado: (2016)

Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation
por: Carbajal-Rodríguez, Luis M., et al.
Publicado: (2021)

Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I
por: Wilson, Amanda, et al.
Publicado: (2021)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Nutrient Status among Latvian Children with Phenylketonuria
por: Lubina, Olga, et al.
Publicado: (2023)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs
por: Gawri, Rahul, et al.
Publicado: (2022)

New-Born Screening for Spinal Muscular Atrophy: Results of a Latvian Pilot Study
por: Gailite, Linda, et al.
Publicado: (2022)

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure
por: de Ru, Minke H, et al.
Publicado: (2011)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
por: Tomita, Kazuyoshi, et al.
Publicado: (2021)

Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB
por: Ellinwood, N. Matthew, et al.
Publicado: (2022)

Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI
por: Eliyahu, Efrat, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4dbsq90vdr177buucu9sjnp2kq